Lepu Medical Tech Beijing

300003.CS▲

Lepu Medical Chairman Pu Zhongjie Increases Stake by 853,700 Shares

Lepu Medical's actual controller and chairman, Pu Zhongjie, increased his stake in the company by 853,700 shares through centralized bidding on August 24, 2026, representing 0.046% of the company's total share capital, at an average transaction price of 11.71 yuan per share. After the increase, Pu Zhongjie's direct shareholding rose from 228 million shares to 229 million shares, and his ownership ratio increased from 12.37% to 12.42%. Pu Zhongjie and his concert parties together hold 456 million shares of the company, accounting for 24.76% of the total share capital. This increase is based on recognition of the company's long-term investment value, and Pu Zhongjie has committed not to reduce his shareholding within six months after the completion of the increase and within the statutory period.

300003.CS ▲

Jiemian·26dRead more →

300003.CS▼

Lepu Medical's 2026 interim net profit was 499 million yuan, down 27.71% year-on-year

Lepu Medical released its 2026 interim report, with net profit attributable to the parent company of 499 million yuan, a decrease of 27.71% compared with the same period last year. The company's total operating revenue was 3.214 billion yuan, down 4.61% year-on-year; net cash inflow from operating activities was 633 million yuan, down 0.60% year-on-year. The company's latest gross margin was 60.86%, a decrease of 3.40 percentage points from the same period last year; the latest ROE was 3.05%, a decrease of 1.33 percentage points from the same period last year. The company's diluted earnings per share was 0.27 yuan, down 27.69% year-on-year.

300003.CS ▼

Jiemian·26dRead more →

300003.CS3

Lepu Medical to transfer 54.2384% stake in Shanghai Minwei Biotech to Xintai Medical for 1.088 billion yuan

Lepu Medical announced that it will transfer its 54.2384% stake in Shanghai Minwei Biotech to its controlling subsidiary Xintai Medical for 1.088 billion yuan. This transaction is an internal equity transfer within the company and does not involve any change in the scope of consolidated financial statements.

300003.CS

CLS·29dRead more →

300003.CS▼

Lepu Medical first-half net profit attributable to parent was 499 million yuan, down 27.7% year on year

Lepu Medical released its 2026 half-year report. Net profit attributable to the parent in the first half was 499 million yuan, down 27.7% year on year. Operating revenue was 3.21 billion yuan, down 4.6% year on year. Net profit attributable to the parent after deducting non-recurring items was 481 million yuan, down 27.4% year on year. Net operating cash flow was 633 million yuan, down 0.6% year on year. Second-quarter operating revenue was 1.54 billion yuan, down 5.6% year on year, and net profit attributable to the parent was 253 million yuan, down 19.1% year on year. The company said volume-based procurement policies have had a significant impact on medical consumables and generic drugs. It is actively expanding self-pay consumer healthcare products, gradually reducing investment in generic drugs, and focusing on innovative drugs in the cardiovascular field.

300003.CS ▼

财中社·29dRead more →

300003.CS▲

Lepu Medical Plans Cash Dividend of 1.6275 Yuan per 10 Shares

Lepu Medical announced plans to distribute a cash dividend of 1.6275 yuan per 10 shares, before tax, to all shareholders, with an estimated total payout of 300 million yuan. In the first half of 2026, the company reported revenue of 3.214 billion yuan and net profit attributable to the parent of 499 million yuan.

300003.CS ▲

财中社·29dRead more →

Biotech & Genomic Medicine▲2

Lepu Medical Subsidiary's MWN117 Injection Approved for Clinical Trials

Shanghai Minwei Biotech, a controlled subsidiary of Lepu Medical, has received a drug clinical trial approval notice for its MWN117 injection from the National Medical Products Administration. The indication is overweight and obesity. The announcement noted that MWN117 is expected to deliver clinical effects such as body fat reduction and muscle maintenance that differ from traditional GLP-1 receptor agonists, while also requiring less frequent dosing. Currently, no similar drug has been approved for market either domestically or internationally. In the first quarter of 2026, Lepu Medical achieved revenue of 1.672 billion yuan and net profit attributable to the parent company of 247 million yuan.

300003.CS ▲

Biotech & Genomic Medicine

财中社·32dRead more →

Biotech & Genomic Medicine▲3

Lepu Medical Subsidiary's MWN110 Injection Approved for Clinical Trials

Lepu Medical's controlled subsidiary, Shanghai Minwei Biotechnology, has received a drug clinical trial approval notice for its MWN110 injection from the National Medical Products Administration. The indication is adult weight management. The drug is a monoclonal antibody targeting ActRIIA/B. Non-clinical studies show it can significantly reduce body fat percentage and body weight while increasing muscle mass. When used in combination with semaglutide, it can inhibit muscle loss, and it has a good safety profile. Currently, no similar drug is on the market domestically or internationally, but subsequent clinical trials carry uncertainty risks.

300003.CS ▲

Biotech & Genomic Medicine

CLS·66dRead more →

300003.CS▼

Lepu Medical's controlling shareholder Pu Zhongjie releases 2.62% stake pledge and pledges 6.13% stake

Lepu Medical's controlling shareholder Pu Zhongjie released the pledge on 11.93 million shares, accounting for 2.62% of his holdings and 0.65% of the company's total share capital. At the same time, he pledged 27.93 million shares, representing 6.13% of his holdings and 1.52% of the company's total share capital. As of the announcement date, Pu Zhongjie has cumulatively pledged 126 million shares, accounting for 55.1% of his holdings and 6.82% of the company's total share capital. In the first quarter of 2026, Lepu Medical achieved revenue of 1.672 billion yuan and net profit attributable to the parent company of 247 million yuan.

300003.CS ▼

财中社·75dRead more →